Vimpat
NDC Package 70166-617-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Vimpat is lacosamide is used to prevent and control seizures. Marketed by Lohxa, this product is identified by NDC 70166-617 and is authorized under FDA application NDA022255.

Identification & Billing

NDC Package Code
70166-617-10
Package Description
20 CUP, UNIT-DOSE in 1 PACKAGE / 5 mL in 1 CUP, UNIT-DOSE
Product Code
70166-617
11-Digit Billing Format
70166061710
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Vimpat
Dosage Form
-
Usage Information
Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Regulatory & Marketing

Labeler Name
Lohxa
FDA Application #
NDA022255
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-20-2010
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70166-617-10 identifies a specific commercial package of 20 cup, unit-dose in 1 package / 5 ml in 1 cup, unit-dose of Vimpat, labeled by Lohxa. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Lohxa on April 20, 2010. The current certification is valid through December 31, 2022.

What are the primary indications for this medication?

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

How is this Lohxa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70166061710. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70166-617-10
11-Digit CMS (5-4-2)
70166-0617-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.